This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CAMBRIDGE, Mass. (
Vertex Pharmaceuticals(VRTX - Get Report) is pairing up with
Johnson & Johnson(JNJ - Get Report) and
GlaxoSmithKline(GSK - Get Report) in separate collaborations that will study new all-oral combination therapies for hepatitis C, the companies said Thursday.
All three companies are trying to catch up with
Gilead Sciences(GILD - Get Report) and
Abbott(ABT - Get Report), which are well ahead in the race to develop all-oral hepatitis C therapies.
Both new collaborations involve Vertex's nucleotide "nuc" polymerase inhibitor VX-135, formerly known as ALS-2200.
VX-135 will be combined with J&J's protease inhibitor simeprevir with and without ribavirin for 12 weeks in treatment-naive, genotype 1 hepatitis C patients. The phase II study is expected to begin in early 2013.
In a separate phase II study, VX-135 will be combined with Glaxo's NS5A inhibitor GSK2336805 with and without ribavirin for 12 weeks in the same type of hepatitis C patients.
Vertex, J&J and Glaxo will pay the costs of the new trials equally by and the collaborations do not involve any up-front or milestone payments.
"We think is a good move for Vertex and should help quell concerns from some investors that the company wanted to prioritize Incivek combo regimens," writes ISI Group analyst Mark Schoenebaum in an email to clients Thursday morning. Incivek is Vertex's currently approved hepatitis C drug but it must be taken three times a day in a combination regimen that includes the injected immune booster interferon.
Adds Schoenebaum: "Recall, however, that there is very little data available for VRTX's nuc [VX-135] at this point -- thus development risk remains high. We include very little 'next generation' Hep C sales in our Vertex model and our thesis is mainly built around the 'combo' cystic fibrosis program."
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Twitter and become a fan on